Promises
2 promises
Promise Tracker
0 delivered, 0 close, 2 missed.
View Promises →
Fortis Healthcare Limited — Q2 FY24
Fortis Healthcare reported a strong Q2 FY24 with consolidated revenue of INR 1,770 crore (+10.1% YoY) and operating EBITDA of INR 330 crore (+8.9% YoY).
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Fortis Healthcare reported a strong Q2 FY24 with consolidated revenue of INR 1,770 crore (+10.1% YoY) and operating EBITDA of INR 330 crore (+8.9% YoY). Hospital revenue grew 12% YoY to INR 1,456 crore, with hospital EBITDA margin improving to 18.4% (vs 18.2% YoY). Key drivers included 11.8% ARPOB growth to INR 2.21 crore, strong traction in oncology (27% growth), and international patient revenue up 15.6%. Brownfield expansion remains on track with 250 beds added this year and a total pipeline of 1,800 beds over 3-4 years. Management reiterated its guidance of 20% hospital EBITDA margin by FY25, supported by occupancy ramp-up and cost focus. Risks include potential delays in bed commissioning and elevated legal costs (INR 6-7 crore this quarter).
फोर्टिस हेल्थकेयर ने दूसरी तिमाही में अच्छा प्रदर्शन किया। कंपनी की कुल कमाई 1,770 करोड़ रुपये रही, जो पिछले साल से 10.1% ज्यादा है। परिचालन मुनाफा (EBITDA) 330 करोड़ रुपये रहा, जो 8.9% बढ़ा। अस्पतालों की कमाई 12% बढ़कर 1,456 करोड़ रुपये हुई। मुनाफा मार्जिन 18.2% से सुधरकर 18.4% हो गया। मरीजों से प्रति बिस्तर कमाई 11.8% बढ़ी। कैंसर इलाज से कमाई 27% और विदेशी मरीजों से 15.6% बढ़ी। कंपनी ने इस साल 250 नए बिस्तर जोड़े और अगले 3-4 साल में 1,800 बिस्तर जोड़ने की योजना है। प्रबंधन को उम्मीद है कि अगले साल तक अस्पतालों का मुनाफा मार्जिन 20% हो जाएगा। जोखिमों में नए बिस्तरों में देरी और कानूनी खर्च (इस तिमाही में 6-7 करोड़ रुपये) शामिल हैं।
Promises0 met · 2 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Legal and professional costs overhang
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Occupancy
68.7%
-90bps YoY
Occupancy declined from 69.6% in Q2 FY23, but improved sequentially from 63.7% in Q1 FY24.
ARPOB
INR 2.21 crore
+12.2% YoY
Average revenue per occupied bed increased from INR 1.97 crore in Q2 FY23, driven by case mix and pricing.
International Patient Revenue
INR 127 crore
+15.6% YoY
International patient revenue grew strongly, contributing 8.3% of hospital revenue vs 8% YoY.
Brownfield Bed Pipeline
1,800 beds
+400 beds vs prior guidance
Expansion pipeline increased from 1,400 to 1,800 beds, including new projects in Mohali and Shalimar Bagh.
What Changed vs Last Quarter
NEW
70% occupancy exit rate in FY24
The company expects to exit FY24 with occupancy around 70%, despite seasonal fluctuations and new bed additions.
NEW
250 beds to be added in FY24
Brownfield expansions at Mulund, Anandapur, BG Road, and Ludhiana will add approximately 250 beds in the current financial year.
UPDATED
20% hospital EBITDA margin by FY25
Management reiterated its target of achieving 20% EBITDA margin for the hospital business in the next financial year, driven by occupancy ramp-up and cost control.
UPDATED
1,800 beds in pipeline over 3-4 years
Total brownfield bed pipeline increased to 1,800 beds, including new projects at Mohali (400 beds) and Shalimar Bagh, plus Manesar (350 beds) over 2.5-3 years.
DROPPED
ARPOB growth of 4-5% for FY24
Management expects ARPOB to grow 4-5% for the full year, moderating from Q1's 12% growth due to base effects.
DROPPED
Occupancy to trend towards 70% over 2-3 years
Management expects occupancy to reach 70% over the medium term, supported by bed additions and ramp-up.
NEW RISK
Legal and professional costs overhang
Elevated legal costs of INR 6-7 crore in Q2 due to ongoing litigation; timing of resolution is uncertain and could continue to pressure margins.
NEW RISK
Doctor cost inflation and talent churn
Analyst raised concern about rising guaranteed payouts for clinicians; management acknowledged some churn but deemed risk low. However, cost pressures could impact margin trajectory.
NEW RISK
Delays in bed commissioning
Management identified potential delays in brownfield bed commissioning as a key risk to achieving FY25 margin targets.
NEW RISK
Low-margin oncology mix drags margins
Rapid growth in medical oncology (lower margin) relative to surgical oncology could cap margin expansion despite absolute EBITDA growth.
RISK GONE
Nursing staff attrition and wage inflation
Management acknowledged industry-wide nursing shortage and wage inflation, which could pressure margins.
RISK GONE
Lower occupancy and unfavorable payer mix
Q1 occupancy at 64% and higher government scheme mix impacted profitability; recovery depends on mix improvement.
RISK GONE
Oncology margin pressure
Oncology growth (34% YoY) comes with lower margins due to revenue sharing, potentially dragging overall hospital margins.
RISK GONE
Delays in bed ramp-up or regulatory approvals
New bed additions and the Manesar acquisition may face delays in commissioning or occupancy ramp-up.
Fast read
Guidance and risk preview
Management reiterated its target of achieving 20% EBITDA margin for the hospital business in the next financial year, driven by occupancy ramp-up a...
Elevated legal costs of INR 6-7 crore in Q2 due to ongoing litigation; timing of resolution is uncertain and could continue to pressure margins.
View Risks →